Dionysus Health Appoints Digital Health Leader Rashmi Raghavendra as Chief Executive Officer
New CEO to Lead Company from Groundbreaking Science to Commercial Launch in Maternal Mental Health Diagnostics
Raghavendra is a globally recognized leader in digital health, diagnostics innovation, and healthcare AI. With more than 20 years of experience transforming early-stage ventures into scalable, revenue-generating companies, she has created over
"Rashmi's appointment marks a transformative milestone for Dionysus Health," said Dr.
Raghavendra joins Dionysus Health at a pivotal time as the company moves from validated, groundbreaking science to full commercialization. The clinically validated diagnostic tool has demonstrated up to 90% predictive accuracy in over 600 participants. It is supported by
- First commercial pilots launching in
Dec 2025 , inFlorida with multiple leading OB-GYN groups - FDA Breakthrough Device Designation in 2026
- Full FDA Device Approval by 2027
Dionysus Health is currently completing its financing efforts to support the upcoming commercial pilots and accelerate regulatory approvals.
"Dionysus Health is redefining what's possible in maternal mental health," said Raghavendra. "By harnessing epigenetics and AI, our technology shifts care from reaction to prevention, empowering clinicians to identify risk for postpartum depression as early as 24 weeks into pregnancy. I'm honored to lead this mission and bring proactive care to women and families who've waited far too long. As both a mother and a healthcare executive, this work is deeply personal."
Visit https://dionysushealth.com/ to learn more about Dionysus Health's innovative approach to maternal mental health and how it plans to make a positive impact on women and families. Explore the company's research, technology, and mission to revolutionize maternal mental health screening.
About Dionysus Health
Dionysus Health is a precision diagnostics company harnessing AI and epigenetics to predict and prevent postpartum depression before it starts. The company's proprietary blood test identifies a woman's risk as early as 24 weeks of pregnancy, using advanced molecular biomarkers and AI-driven pattern recognition to detect biological changes months before symptoms arise. Clinically validated in more than 600 participants with up to 90% predictive accuracy, the diagnostic has been supported by
Rashmi's Contact Info:
[email protected]
Rashmi's LinkedIn
Media Contact: [email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/dionysus-health-appoints-digital-health-leader-rashmi-raghavendra-as-chief-executive-officer-302623938.html
SOURCE Dionysus Health
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Georgia Power's contract with OpenAI approved; Latest approval part of portfolio of large-load contracts delivering approximately $950 million in annual savings beginning in 2029
- GotRot Calls Attention to Crawl Space Moisture Risks in Greater Seattle Homes Ahead of Rainy Season
- Gigasoft 2026 JavaScript Chart Comparison: ProEssentials, Highcharts, SciChart, LightningChart, ECharts
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share